France Biotech announces its 5th Bioethics Forum

France Biotech, the French association of life science businesses and their partners (www.france-biotech.org) today announced that its 5th Bioethics Forum (organized in collaboration with the Eurobiomed cluster) will take place on Friday, December 11th, at the Musée du Carre d’Art venue in Nîmes.

Today, new treatments rely primarily on the pharmaceutical development of new chemical or biological entities. Even though pharmaceutical industry R&D budgets continue to increase in both Europe and North America, the number of new therapeutics that reach the market has fallen well short of what could be expected of these levels of investment.

The development of complex bioprostheses is one of the most promising new approaches in medicine and should be a valuable addition to the physician's therapeutic arsenal. This field leverages progress in computing, chemistry, mechanical engineering, information technology and biotechnology. France Biotech and Eurobiomed wish to anticipate the ethical issues linked to the arrival of these new, intelligent medical devices.

As in previous editions, the Nîmes Bioethics Forum will enable life science company managers to meet and dialogue with a panel of experts (philosophers, healthcare professionals, etc.) in order to identify ethical questions raised by medical applications of these new technologies and thus to plan their device development in accordance with ethical principles.

One practical goal for the biotech stakeholders attending the Forum is to update the ethical principles in France Biotech's Ethical Code of Practice.

France Biotech and its members intend to continue their initiatives in this field by issuing and defending clear, independent points of view based on the evaluation and regular updating of scientific, technological and societal data.

One of Eurobiomed's missions is the socially responsible development of the healthcare sector. The cluster has decided to co-organize the Bioethics Forum with France Biotech so that its members can become proactive stakeholders in this field.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA strengthens AI regulation to ensure patient safety and innovation in healthcare